Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
Lantern Pharma (NASDAQ: LTRN) has reported a complete metabolic response in a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell DLBCL during its ongoing Phase 1 trial of LP-284. This marks the first such response observed with the candidate, highlighting its potential as a paradigm-shifting therapy for refractory lymphomas. The patient, who had failed three prior regimens including CAR-T and bispecific antibody therapy, responded after just two cycles of LP-284. Developed using Lantern's RADR(R) AI platform, LP-284's synthetic lethal mechanism supports accelerated development in the $4 billion global B-cell cancer market. For more details, visit https://ibn.fm/TCGHH.